301 related articles for article (PubMed ID: 23894201)
1. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.
Sohn SJ; Barrett K; Van Abbema A; Chang C; Kohli PB; Kanda H; Smith J; Lai Y; Zhou A; Zhang B; Yang W; Williams K; Macleod C; Hurley CA; Kulagowski JJ; Lewin-Koh N; Dengler HS; Johnson AR; Ghilardi N; Zak M; Liang J; Blair WS; Magnuson S; Wu LC
J Immunol; 2013 Sep; 191(5):2205-16. PubMed ID: 23894201
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.
Works MG; Yin F; Yin CC; Yiu Y; Shew K; Tran TT; Dunlap N; Lam J; Mitchell T; Reader J; Stein PL; D'Andrea A
J Immunol; 2014 Oct; 193(7):3278-87. PubMed ID: 25156366
[TBL] [Abstract][Full Text] [Related]
3. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
4. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
[TBL] [Abstract][Full Text] [Related]
6. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
7. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
[TBL] [Abstract][Full Text] [Related]
8. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
Strobl B; Stoiber D; Sexl V; Mueller M
Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
[TBL] [Abstract][Full Text] [Related]
10. The
Gorman JA; Hundhausen C; Kinsman M; Arkatkar T; Allenspach EJ; Clough C; West SE; Thomas K; Eken A; Khim S; Hale M; Oukka M; Jackson SW; Cerosaletti K; Buckner JH; Rawlings DJ
Front Immunol; 2019; 10():44. PubMed ID: 30740104
[TBL] [Abstract][Full Text] [Related]
11. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.
Minegishi Y; Saito M; Morio T; Watanabe K; Agematsu K; Tsuchiya S; Takada H; Hara T; Kawamura N; Ariga T; Kaneko H; Kondo N; Tsuge I; Yachie A; Sakiyama Y; Iwata T; Bessho F; Ohishi T; Joh K; Imai K; Kogawa K; Shinohara M; Fujieda M; Wakiguchi H; Pasic S; Abinun M; Ochs HD; Renner ED; Jansson A; Belohradsky BH; Metin A; Shimizu N; Mizutani S; Miyawaki T; Nonoyama S; Karasuyama H
Immunity; 2006 Nov; 25(5):745-55. PubMed ID: 17088085
[TBL] [Abstract][Full Text] [Related]
12. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
13. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.
Gracey E; Hromadová D; Lim M; Qaiyum Z; Zeng M; Yao Y; Srinath A; Baglaenko Y; Yeremenko N; Westlin W; Masse C; Müller M; Strobl B; Miao W; Inman RD
J Clin Invest; 2020 Apr; 130(4):1863-1878. PubMed ID: 32149730
[TBL] [Abstract][Full Text] [Related]
14. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.
Shimoda K; Kato K; Aoki K; Matsuda T; Miyamoto A; Shibamori M; Yamashita M; Numata A; Takase K; Kobayashi S; Shibata S; Asano Y; Gondo H; Sekiguchi K; Nakayama K; Nakayama T; Okamura T; Okamura S; Niho Y; Nakayama K
Immunity; 2000 Oct; 13(4):561-71. PubMed ID: 11070174
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis and impaired IL-23-dependent IFN-γ immunity in humans homozygous for a common
Boisson-Dupuis S; Ramirez-Alejo N; Li Z; Patin E; Rao G; Kerner G; Lim CK; Krementsov DN; Hernandez N; Ma CS; Zhang Q; Markle J; Martinez-Barricarte R; Payne K; Fisch R; Deswarte C; Halpern J; Bouaziz M; Mulwa J; Sivanesan D; Lazarov T; Naves R; Garcia P; Itan Y; Boisson B; Checchi A; Jabot-Hanin F; Cobat A; Guennoun A; Jackson CC; Pekcan S; Caliskaner Z; Inostroza J; Costa-Carvalho BT; de Albuquerque JAT; Garcia-Ortiz H; Orozco L; Ozcelik T; Abid A; Rhorfi IA; Souhi H; Amrani HN; Zegmout A; Geissmann F; Michnick SW; Muller-Fleckenstein I; Fleckenstein B; Puel A; Ciancanelli MJ; Marr N; Abolhassani H; Balcells ME; Condino-Neto A; Strickler A; Abarca K; Teuscher C; Ochs HD; Reisli I; Sayar EH; El-Baghdadi J; Bustamante J; Hammarström L; Tangye SG; Pellegrini S; Quintana-Murci L; Abel L; Casanova JL
Sci Immunol; 2018 Dec; 3(30):. PubMed ID: 30578352
[TBL] [Abstract][Full Text] [Related]
16. IκB-ζ Expression Requires Both TYK2/STAT3 Activity and IL-17-Regulated mRNA Stabilization.
Muromoto R; Tawa K; Ohgakiuchi Y; Sato A; Saino Y; Hirashima K; Minoguchi H; Kitai Y; Kashiwakura JI; Shimoda K; Oritani K; Matsuda T
Immunohorizons; 2019 May; 3(5):172-185. PubMed ID: 31356171
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
[TBL] [Abstract][Full Text] [Related]
18. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation.
Shaw MH; Freeman GJ; Scott MF; Fox BA; Bzik DJ; Belkaid Y; Yap GS
J Immunol; 2006 Jun; 176(12):7263-71. PubMed ID: 16751369
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Gerstenberger BS; Ambler C; Arnold EP; Banker ME; Brown MF; Clark JD; Dermenci A; Dowty ME; Fensome A; Fish S; Hayward MM; Hegen M; Hollingshead BD; Knafels JD; Lin DW; Lin TH; Owen DR; Saiah E; Sharma R; Vajdos FF; Xing L; Yang X; Yang X; Wright SW
J Med Chem; 2020 Nov; 63(22):13561-13577. PubMed ID: 32787094
[TBL] [Abstract][Full Text] [Related]
20. Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells.
Nakamura R; Shibata K; Yamada H; Shimoda K; Nakayama K; Yoshikai Y
J Immunol; 2008 Aug; 181(3):2071-5. PubMed ID: 18641345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
